Plant Extract Reduces Gut Inflammation and Preserves Barrier Function in Colitis Model
A traditional East Asian herbal extract suppresses inflammasome activation and protects intestinal barriers in experimental colitis.
A traditional medicinal plant extract derived from the winged cork of Euonymus alatus significantly lessened colon damage and body weight loss in mice with chemically induced colitis, pointing to a potential new avenue for treating inflammatory bowel disease. The hydroethanolic plant extract, tested across a range of doses in male C57BL/6 mice, successfully suppressed gut inflammation and preserved the protective layer of cells lining the intestines.
How the Plant Extract Protected Against Colitis Damage
Inflammatory bowel disease, which includes ulcerative colitis and Crohn’s disease, affects millions of people worldwide by causing chronic, relapsing inflammation in the digestive tract. Conventional treatments such as corticosteroids and biologics often carry risks of opportunistic infections and other adverse side effects. Seeking safer alternatives, researchers investigated Euonymus alatus, a shrub long used in East Asian traditional medicine for abdominal pain and dysentery.
In the controlled study published in Pharmaceutical biology, scientists induced experimental colitis in mice using 2.0% dextran sulfate sodium in their drinking water over multiple cycles. Mice treated with the plant extract experienced notably less severe body weight loss and lower disease activity index scores than untreated mice with colitis. Furthermore, the higher-dose extract group maintained longer colons, averaging 7.58 centimeters compared to 6.67 centimeters in the untreated disease group.
Targeting the Cellular Machinery of Inflammation
To understand the biological mechanisms behind these protective effects, the research team performed RNA sequencing and cellular assays. The analysis revealed that the extract lowered the expression of several key inflammatory genes, including the gene responsible for the NLRP3 inflammasome, a multi-protein complex that drives excessive immune responses and tissue destruction in the gut.
When researchers examined immune cells known as macrophages in laboratory dishes, they found that the plant extract suppressed a destructive form of programmed cell death called pyroptosis. Specifically, the treatment reduced the release of damaging signaling proteins such as interleukin-1 beta and interleukin-18, while also preventing the formation of speck structures that assemble during inflammasome activation.
Preserving Intestinal Barrier Integrity
A hallmark of inflammatory bowel disease is the breakdown of the epithelial barrier, which allows gut bacteria to leak into surrounding tissues and trigger runaway immune reactions. In human Caco-2 cell monolayers subjected to inflammatory cytokines, the plant extract improved transepithelial electrical resistance and reduced molecular permeability.
Immunohistochemical staining of mouse colonic tissues confirmed that the treatment helped maintain expression of crucial tight junction proteins, specifically ZO-1 and occludin, which normally vanish during severe colitis flares. This preservation of physical barriers correlated with reduced infiltration of neutrophils and macrophages into the damaged colon tissue.
Identifying Active Chemical Constituents
Using ultra-high-performance liquid chromatography tandem mass spectrometry, the investigators profiled fourteen distinct phytochemicals within the extract. These included various flavonoids and phenolic acids such as catechin, epicatechin, taxifolin, and quercetin. When tested individually on macrophages, these four flavonoid-related compounds partially reproduced the anti-inflammatory effects of the whole extract by reducing lactate dehydrogenase release and lowering cleaved caspase-1 levels.
Despite these promising laboratory and animal findings, the authors emphasize several limitations. The animal model used reflects acute epithelial injury rather than the full complexity of human inflammatory bowel disease. Additionally, the relative contributions of individual plant constituents remain to be fully mapped, and formal clinical trials in humans are necessary before any therapeutic recommendations can be made.
The research was published in Pharmaceutical biology on November 18, 2026.
This article has been fact checked for accuracy, with information verified against reputable sources. Learn more about us and our editorial process.
Last reviewed on .
Article history
- Latest version
Cite this page:
- Posted by Elizabeth Taylor